Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients With Primary and Secondary Liver Cancer

Next Previous
X
Search
Trial Profile

Phase 1/2a Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients With Primary and Secondary Liver Cancer

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezurpimtrostat (Primary)
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Liver cancer; Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Sponsors Genoscience

    • Most Recent Events

    • 25 Apr 2022 Status changed from recruiting to discontinued. Reason the study was stopped: only phase 1b was completed and the phase 2 will be an another study, finally
    • 15 Nov 2021 Results (n=19) presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
    • 08 Jun 2021 Results (n=19) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top